Floatz logo

URACIL RIBOSIDE

Hyperlactatemia

National Center for Complementary and Integrative Health (NCCIH)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hyperlactatemia cohort.

Asset / SponsorPhaseRating
DL-DOBUTAMINE
Federal University of São Paulo
Phase 2CCC
Thiamine
Universiti Kebangsaan Malaysia Medical Centre
N/AD
METOCLOPRAMIDE
Universiti Kebangsaan Malaysia Medical Centre
N/AD
Solu-Cortef
Universiti Kebangsaan Malaysia Medical Centre
N/AD

Same molecule, other indications

URACIL RIBOSIDE is also rated in:

lipodystrophyDormant
BB
Indicative ·
70 / 100
View asset →
HIV infectious diseaseDormant
BB
Indicative ·
69 / 100
View asset →
metabolic diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →